Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis - Takeaways - MDSpire

Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis

  • By

  • Andreas Karlsson Rosenblad

  • Bassam Mazin Hashim

  • Per Lindblad

  • Börje Ljungberg

  • August 7, 2024

  • 0 min

Share

  • 1

    Partial nephrectomy (PN) and ablative therapy (AT) for localized nonmetastatic renal cell carcinoma carry risks for local and distant metastatic recurrence.

  • 2

    Local recurrence (LR) occurs in 14% of AT cases and 3% of PN cases, with higher rates linked to larger tumors and advanced stages.

  • 3

    Surgical removal of locally recurrent disease can achieve durable control if negative margins are obtained, despite potential complications.

  • 4

    The study analyzed 2751 tumors, revealing LR in 4.0% and distant metastatic recurrence (DMR) in 3.9% of cases after a mean follow-up of 4.8 years.

  • 5

    AT-treated patients were older and had smaller tumors compared to PN-treated patients, indicating differences in treatment demographics and tumor characteristics.

Original Source(s)

Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis

  • by Andreas Karlsson Rosenblad, Bassam Mazin Hashim, Per Lindblad, Börje Ljungberg

  • August 7, 2024

Related Content

Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

  • February 26, 2025

  • 1 min
Renal clear cell carcinoma with co-existing tumor thrombosis of renal vein and ureter: a case report and review of the literature

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma